Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

cytomegalovirus immune globulin, intravenous

Known as: CMVIG 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Snydman DR, Kistler KD, Ulsh P, Bergman GE, Vensak J, Morris J. The impact of CMV prevention on long‐term recipient and graft… Expand
Highly Cited
2008
Highly Cited
2008
Abstract.  Objective:  The goal of this meta‐analysis was to investigate the impact of cytomegalovirus hyperimmune globulin… Expand
Highly Cited
2006
Highly Cited
2006
Background. Anticytomegalovirus (CMV) prophylaxis prevents the acute disease but its impact on subclinical infection and… Expand
Highly Cited
2001
Highly Cited
2001
Background. Cytomegalovirus (CMV) disease was previously shown to be unaltered by a 28-day course of ganciclovir compared with… Expand
Review
2000
Review
2000
Abstract Cyromegalovirus (CMV) is a ubiquitous herpesvirus that, together with human herpesvirus type 6 (HHV- 6) and HHV- 7… Expand
Highly Cited
1997
Highly Cited
1997
PURPOSE To assess impact of cytomegalovirus (CMV) donor-recipient serostatus, infection, or disease on development of invasive… Expand
Highly Cited
1997
Highly Cited
1997
Cytomegalovirus (CMV) causes considerable morbidity and mortality in orthotopic liver transplant (OLT) recipients. Several… Expand
1995
1995
We undertook a randomized, placebo‐controlled, double blind trial of cytomegalovirus (CMV) immunoglobulin (CMVIG) for prevention… Expand
Review
1993
Review
1993
The use of CMVIG, approved in 1990 for prophylactic administration in seronegative recipients of kidneys from seropositive donors… Expand